Browse the corpus

The rupture of a Charcot–Bouchard aneurysm constitutes a major cause of spontaneous intracerebral hemorrhage, predominantly affecting deep cerebral structures, including the basal ganglia, thalamus, pons, and cerebellum. These microaneurysms arise primarily from chronic hypertension, which induces degenerative changes in small penetrating arteries, although additional risk factors, such as advanced age, diabetes mellitus, and cerebrovascular atherosclerosis, contribute to their development. The pathophysiology involves lipohyalinosis and fibrinoid necrosis of small penetrating arteries, resulting in vessel wall weakening that predisposes aneurysms to rupture and subsequent spontaneous intracerebral hemorrhage. Clinical presentation varies with hemorrhage location and volume, commonly manifesting as acute focal neurological deficits, headache, nausea, and decreased level of consciousness. Diagnosis relies on neuroimaging findings, with noncontrast computed tomography demonstrating intracerebral bleeding, while magnetic resonance imaging and angiography assist in characterizing vascular pathology. Management is primarily supportive and may include blood pressure control, reversal of anticoagulation, and surgical intervention when indicated. Complications include direct mass effect on brain tissue, hydrocephalus, and secondary ischemic injury. The prognosis depends on hemorrhage size, location, and the timeliness of intervention. This activity for healthcare professionals aims to enhance providers' competence in evaluating and managing Charcot–Bouchard aneurysms. Participants will gain a deeper understanding of the condition’s etiology, associated risk factors, pathophysiology, clinical presentation, and evidence-based diagnostic and therapeutic recommendations. Enhanced skills will allow clinicians to collaborate effectively with interprofessional teams caring for affected individuals. Objectives: Screen patients for Charcot–Bouchard aneurysm risk factors, prioritizing interventions according to individual comorbidities and clinical urgency. Implement evidence-based, personalized approaches for managing Charcot–Bouchard aneurysms and mitigating their possible complications.

This activity for healthcare professionals aims to enhance providers' competence in evaluating and managing Charcot–Bouchard aneurysms. Participants will gain a deeper understanding of the condition’s etiology, associated risk factors, pathophysiology, clinical presentation, and evidence-based diagnostic and therapeutic recommendations. Enhanced skills will allow clinicians to collaborate effectively with interprofessional teams caring for affected individuals. Objectives: Screen patients for Charcot–Bouchard aneurysm risk factors, prioritizing interventions according to individual comorbidities and clinical urgency. Implement evidence-based, personalized approaches for managing Charcot–Bouchard aneurysms and mitigating their possible complications. Develop strategies for educating individuals at risk for Charcot–Bouchard aneurysm formation regarding blood pressure control, lifestyle modifications, prompt recognition of warning signs, and seeking timely care. Collaborate with all members of the interprofessional team, including specialists such as neurosurgeons, neurologists, and cardiologists, to provide efficient, comprehensive, and coordinated care for individuals who are at risk for or have Charcot–Bouchard aneurysms. Access free multiple choice questions on this topic.

Charcot–Bouchard aneurysms are microaneurysms occurring in small penetrating cerebral vessels with diameters under 300 µm. The lenticulostriate arteries (LSAs) of the middle cerebral artery (MCA) are the most frequently involved. The LSAs arise from the M1 segment of the MCA, typically near its origin but variably along the segment, with numbers ranging from 2 to 12 (mean 8.1). Most branches originate from the proximal M1 segment, often from the superior or posterior surface adjacent to the internal carotid artery. These vessels supply the basal ganglia, which include the putamen, caudate, and portions of the globus pallidus, as well as the adjacent internal capsule.[1] Charcot–Bouchard aneurysms are named after the French physician Jean-Martin Charcot and his student Charles Jacques Bouchard, who first described these microvascular lesions in 1866.[2] Bouchard identified these aneurysms during his research under Charcot. Cole and Yates substantiated Charcot and Bouchard’s observations by demonstrating the existence of aneurysms using microangiography in the 1960s. Debate persists regarding whether the rupture of these aneurysms is responsible for intracerebral hemorrhage (ICH).[3] Emerging evidence suggests that Charcot–Bouchard lesions are uncommon and may represent advanced small vessel disease, as many deep ICHs occur without a demonstrable ruptured microaneurysm.[4] Chronic systemic hypertension increases the risk of lipohyalinosis and fibrinoid necrosis with smooth muscle loss in small penetrating arteries. Loss of vessel wall integrity allows microaneurysm-like dilatations to form in penetrating arterioles, including lenticulostriate vessels, which can rupture and contribute to deep ICH. Clinical deficits generally correspond to the location of the hemorrhage. Noncontrast computed tomography (CT) of the head represents the primary diagnostic modality for visualizing ICH. Management strategies vary according to the hemorrhage size and location, ranging from observation alone to neurosurgical intervention with hematoma evacuation.[5][6]

Chronic systemic hypertension is the principal risk factor for deep ICH and is associated with hypertensive small vessel arteriopathy, including Charcot–Bouchard microaneurysm–like changes. Risk factors may be classified as modifiable and nonmodifiable. Modifiable factors include hypertension, high-salt or low–fruit-and-vegetable diets, elevated waist-to-hip ratio, smoking, excessive alcohol consumption, the use of illicit sympathomimetic drugs, such as cocaine or amphetamines, and increased very low-density lipoprotein cholesterol, each associated with increased ICH risk in some studies. Nonmodifiable factors include advanced age, male sex, and race, with Asians and African Americans at higher risk. Additional contributors to ICH risk include chronic kidney disease, cerebral amyloid angiopathy (CAA), vascular malformations, hereditary or acquired coagulopathies, and pharmacologic anticoagulation or antiplatelet therapy.[7][8]

ICH accounts for 10% to 20% of all strokes worldwide and 8% to 15% of strokes in the US. In 2016, the lifetime risk of stroke among adults aged 25 and older was estimated to be 24.7% for men and 25.1% for women, yielding an overall risk of 24.9%, compared to 22.8% in 1990. The highest risk occurs in East Asia and Europe, whereas the lowest risk is observed in low sociodemographic index regions, such as sub-Saharan Africa. Stroke incidence and mortality are highest in Asia, particularly in China, and in Eastern European countries. Although age-adjusted stroke rates are declining, the absolute number of incident cases in 2016 has doubled since 1990, with most affected individuals being younger than 70 years. The estimated case fatality for ICH is 40% at 1 month and 54% at 1 year. Long-term functional independence is achieved in only 13% to 49% of patients.[9]

LSAs are small perforating end arteries that arise from the MCA. Chronic hypertension subjects these vessels to sustained wall stress and promotes arteriolar remodeling. Hemodynamic changes in blood pressure, blood velocity, and diameter at the branching points from arterioles to capillaries increase the shear forces within LSAs. Prolonged hypertension induces hypertensive small vessel arteriopathy, including changes such as lipohyalinosis and fibrinoid necrosis, resulting in weakening of the arteriolar wall and formation of microaneurysm-like dilatations. Rupture of diseased penetrating arterioles, occasionally involving microaneurysm-like dilatations, can produce hemorrhage and hematoma formation in deep brain structures, most commonly the basal ganglia. Disruption of the surrounding brain parenchyma and mass effect on adjacent neural structures occur following aneurysmal rupture. Multiple inflammatory pathways become activated through several mechanisms, including the following: Extravasation of blood-derived inflammatory mediators into the perihematomal region Mechanical disruption of neural and glial tissue Hemoglobin breakdown resulting in neuronal injury Activation of the coagulation cascade and elevated thrombin levels, which amplify proinflammatory processes Hematoma expansion occurs predominantly within the first few hours after the hemorrhage but can continue during the initial 24 hours. Perihematomal edema typically peaks at around 5 days, occasionally extending to 1 to 2 weeks after the onset. Increased intracranial pressure (ICP) can reduce cerebral perfusion pressure, increasing the risk of secondary ischemic injury.[10]

The wall of small penetrating arteries consists of 3 layers: tunica intima, tunica media, and tunica adventitia. Endothelial cells express endothelial nitric oxide synthase, producing nitric oxide that mediates vasodilation in response to acetylcholine, substance P, and bradykinin. Nerve fibers distributed within the tunica media and adventitia are predominantly sympathetic. Chronic hypertension induces hypertrophy of the smooth muscle layer in response to persistently elevated intraluminal pressure. Sustained hypertension causes arteriolar wall thickening and degenerative changes, including lipohyalinosis and fibrinoid necrosis, progressively weakening small penetrating arteries. Subsequent sclerosis affects the tunica media and, over time, the entire vessel wall. A similar pathological sequence of events occurs in CAA, where β-amyloid deposition within cortical and leptomeningeal vessel walls weakens the vascular structure, predisposing to a lobar ICH.[11] Chronic vascular injury leads to replacement of the collagen fiber network with hyalin, creating areas of low resistance that are susceptible to aneurysmal dilatation and rupture during sudden elevations in blood pressure. Hematoma size reflects the extent and duration of bleeding, as well as the coagulation status. LSAs are particularly vulnerable because the deep brain structures surrounding these arterioles and the capillaries are limited in their ability to accommodate high-pressure fluctuations.[12] Deep ICH involving the basal ganglia, thalamus, pons, and cerebellum is characteristic of hypertensive arteriopathy. Lobar ICH and multiple cortical microbleeds are more typical of CAA.

History The clinical history should begin with the symptom onset and the progression of neurological deficits. ICH may arise during physical activity, emotional stress, or a resting period in patients with predisposing risk factors. Common presenting symptoms include headache secondary to increased ICP and meningeal irritation when subarachnoid extension is present, nausea and vomiting related to ICP elevation, and a decreased level of consciousness ranging from confusion to coma, depending on the hemorrhage location, volume, intraventricular extension, presence of hydrocephalus, and degree of mass effect. Seizures occur within the first 24 hours in approximately 10% of patients.[13] The history should also include screening for risk factors, such as chronic hypertension and the use of anticoagulant or antiplatelet agents. Comorbid conditions, including liver disease and malignancy, should be evaluated due to their association with coagulopathy. Patients with CAA may additionally present with cognitive dysfunction. Physical Accurate measurement of the vital signs, a baseline Glasgow Coma Scale (GCS) score, and a complete physical examination, including a structured neurological assessment, are essential. Neurological symptoms may progress within minutes to hours due to increasing hematoma size and cerebral edema. Specific deficits correspond to the location of hemorrhage. Putaminal lesions typically produce contralateral hemiparesis, variable sensory deficits, and gaze deviation toward the affected side. A thalamic bleed more prominently causes hemianesthesia than hemiparesis and may produce a vertical gaze palsy, often impairing upgaze. Pontine hemorrhage presents with pinpoint pupils, quadriparesis, and coma, and may produce an ipsilesional horizontal gaze palsy with the eyes deviating away from the hemorrhage.[14] Lobar vascular rupture commonly manifests as hemiparesis, hemisensory deficits, and speech impairment. A cerebellar bleed produces vertigo, ataxia, and unilateral paralysis of conjugate gaze.

Laboratory Evaluation The laboratory workup for patients with ICH should include a complete blood count to assess for infection and anemia. Coagulation studies, including prothrombin time, international normalized ratio, and activated partial thromboplastin time, are essential in all patients. Assays specific for direct oral anticoagulant (DOAC) activity should be obtained when clinically indicated. Daily monitoring of electrolytes, creatinine, and liver function tests is recommended. Baseline blood glucose and hemoglobin A1c levels should be established and monitored closely, as hyperglycemia may develop as a complication of ICH. Blood cultures are indicated in patients with suspected systemic infection. Cardiac-specific troponin levels are associated with worse outcomes in this population. Urine toxicology screening is necessary to identify risk factors, such as cocaine use. Lumbar puncture is reserved for selected cases of suspected subarachnoid hemorrhage when imaging results are unremarkable or equivocal, provided mass effect, midline shift, or obstructive hydrocephalus has been excluded by imaging. This procedure may also be performed for suspected infection when imaging confirms the absence of a mass lesion, significant midline shift, effaced basal cisterns, or hydrocephalus. Radiographic Evaluation Noncontrast CT of the head is the primary imaging modality for detecting the presence of an ICH. CT findings may be staged according to the interval from symptom onset, with appearance evolving based on hematoma size and patient-specific factors. The hematoma appears hyperdense in the hyperacute phase. Heterogeneous density or blood–fluid levels may be observed over the subsequent 1 to 2 days. The presence of blood fluid levels may indicate coagulopathy. Perihematomal hypodensity and mass effect may develop within hours and typically progress over the first several days.

Noncontrast CT of the head is the primary imaging modality for detecting the presence of an ICH. CT findings may be staged according to the interval from symptom onset, with appearance evolving based on hematoma size and patient-specific factors. The hematoma appears hyperdense in the hyperacute phase. Heterogeneous density or blood–fluid levels may be observed over the subsequent 1 to 2 days. The presence of blood fluid levels may indicate coagulopathy. Perihematomal hypodensity and mass effect may develop within hours and typically progress over the first several days. Several noncontrast CT features indicate hematomas with a tendency for rapid enlargement and unfavorable outcomes. Intrahematoma hypodensities, including heterogeneous or “swirl”-type areas, suggest active bleeding or incomplete clotting. The blend sign presents as a 2-density hematoma with a sharply demarcated interface. The black hole sign appears as a hypodense region within a hyperdense clot. The island sign consists of multiple small hemorrhagic foci near or within the primary hematoma, whereas the satellite sign identifies small, separate hemorrhages adjacent to the main lesion. Irregular hematoma shape or margins serve as simple morphological markers. CT angiography (CTA) may reveal the CTA spot sign.[15] This finding represents contrast extravasation and correlates with an increased risk of hematoma expansion and a worse prognosis. As density decreases during the late subacute phase, approximately 3 to 20 days after onset, the lesion may exhibit increased heterogeneity with an irregular, ring-like appearance. Repeat CT imaging is indicated in the presence of neurological deterioration to assess for complications. A brain magnetic resonance imaging (MRI) scan with gradient-echo sequences allows for a more accurate detection of microhemorrhages, which appear as small hypointense foci with blooming on susceptibility-sensitive sequences. Although noncontrast CT provides rapid and sensitive detection of acute hemorrhage, MRI can assist in characterizing the age of the hemorrhage and identifying chronic blood products. High-field 7-Tesla MRI is currently employed in research to detect Charcot–Bouchard aneurysms in vivo in humans.[16]

A brain magnetic resonance imaging (MRI) scan with gradient-echo sequences allows for a more accurate detection of microhemorrhages, which appear as small hypointense foci with blooming on susceptibility-sensitive sequences. Although noncontrast CT provides rapid and sensitive detection of acute hemorrhage, MRI can assist in characterizing the age of the hemorrhage and identifying chronic blood products. High-field 7-Tesla MRI is currently employed in research to detect Charcot–Bouchard aneurysms in vivo in humans.[16] Cerebral angiography is indicated to evaluate secondary causes of ICH, including arteriovenous malformations, aneurysms, and dural arteriovenous fistulae in selected patients.[17] Charcot–Bouchard aneurysms may occasionally be visualized using CTA or digital subtraction cerebral angiography. Other Studies Electroencephalography (EEG) is indicated in patients with unexplained neurological deterioration or suspected seizures. Electrocardiography (ECG) is performed to evaluate for cardiac events and arrhythmias.

ICH management begins with securing the airway and supporting ventilation, controlling blood pressure, and maintaining circulation while avoiding hypotension. Patients with a GCS score below 8 typically require intubation and mechanical ventilation. Anticoagulation reversal should be performed if the patient is receiving pertinent medications. The risk of rapid neurological deterioration is greatest within the first 24 hours, necessitating intensive care unit monitoring. Blood pressure should be lowered cautiously in patients with ICH. In cases of mild-to-moderate ICH with systolic blood pressure (SBP) of 150 to 220 mm Hg, acute reduction to a target of 140 mm Hg, maintaining SBP in the range of 150 to 220 mm Hg, is safe and reasonable. Lowering SBP below 130 mm Hg may be harmful. For patients with SBP above 220 mm Hg, controlled reduction using a continuous intravenous infusion with frequent monitoring is recommended, aiming for a blood pressure of 140 to 160 mm Hg while avoiding hypotension. Blood pressure management must balance blood pressure reduction with maintenance of adequate cerebral perfusion pressure, and measurements should be performed at frequent intervals, such as every 5 minutes. Recommended antihypertensive agents include nicardipine, clevidipine, labetalol, esmolol, enalaprilat, fenoldopam, and phentolamine. Following patient stabilization, a neurosurgical consultation is required to assess for intracranial hypertension. Short-term interventions, such as administering intravenous mannitol boluses, hypertonic saline, or hyperventilation, may be considered in cases of acutely worsening cerebral edema to maintain adequate cerebral perfusion. Surgical procedures, including decompressive craniectomy, are indicated for selected ICH cases to reduce mass effect and manage intracranial hypertension. Early surgery may be considered for superficial lobar hematomas (eg, 10–100 mL within 1 cm of the cortical surface) in patients without intraventricular hemorrhage (IVH) who are not comatose, potentially offering a modest survival benefit.

Surgical procedures, including decompressive craniectomy, are indicated for selected ICH cases to reduce mass effect and manage intracranial hypertension. Early surgery may be considered for superficial lobar hematomas (eg, 10–100 mL within 1 cm of the cortical surface) in patients without intraventricular hemorrhage (IVH) who are not comatose, potentially offering a modest survival benefit. Management of concomitant IVH and obstructive hydrocephalus includes ventriculostomy placement with external ventricular drainage (EVD) in patients with enlarging ventricles on CT and neurological deterioration. Antiseizure medication should be administered for ictal activity confirmed by clinical evaluation or EEG. Routine prophylactic therapy should be avoided in patients without clinical or EEG evidence of seizures. Other important therapeutic interventions include the following: Elevation of the head of the bed to 30° Prevention of hyperthermia Correction of hypoglycemia with 50% dextrose and management of hyperglycemia (serum glucose >200 mg/dL) with insulin Continuous cardiac monitoring Bladder catheterization to relieve urinary retention or incontinence and measure urine output accurately Maintenance of nil per os status, with adequate nutrition via nasogastric tube as indicated Prevention of deep vein thrombosis (DVT) Avoidance of pressure ulcers Mild sedation for patient comfort as needed The overall management focuses on patient stabilization, cautious blood pressure reduction, maintenance of adequate cerebral perfusion, and active management of complications as they arise.[18][19]

Differentiation of ICH from lacunar infarction and other causes of acute focal neurological deficits is essential. In deep ICH, hypertensive small vessel arteriopathy affecting penetrating arteries, including lenticulostriate arterioles, causes vessel wall weakening and rupture, occasionally with microaneurysm-like dilatations. Lacunar infarcts typically result from occlusion of small perforating arteries secondary to hypertensive and diabetic small vessel disease.[20]

Key clinical trials have evaluated therapeutic interventions and strategies to reduce hematoma expansion and improve outcomes in ICH. These investigations are explained below. The FAST (Factor VII for Acute Hemorrhagic Stroke) trial demonstrated that recombinant factor VIIa reduced hematoma expansion but did not improve survival or functional outcomes and even increased thromboembolic risk.[21] Trials of tranexamic acid in CTA spot-sign–positive ICH, including SPOTLIGHT and STOP-IT, failed to show consistent reduction in hematoma expansion or improvement in clinical outcomes.[22] The STICH (Surgical Trial in Intracerebral Hemorrhage) trials compared early surgical intervention with initial conservative management. STICH I reported no overall benefit of early surgery, whereas STICH II, which evaluated selected superficial lobar ICH without IVH, found that early surgery did not increase death or disability at 6 months and may confer a modest survival advantage.[23] The ATTACH II (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial assessed intensive SBP reduction in acute hypertensive ICH. Lowering SBP to 110 to 139 mm Hg did not reduce death or disability compared with standard treatment and was associated with an increased incidence of renal adverse events.[24] INTERACT II (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial II) evaluated rapid blood pressure lowering with a target below 140 mm Hg compared to guideline-based management (<180 mm Hg). Intensive reduction did not significantly diminish death or major disability but was associated with improved functional outcome on ordinal analysis.[25] In selected patients with large IVH managed with an EVD for obstructive hydrocephalus, intraventricular alteplase may be considered in experienced centers to accelerate clot clearance. The CLEAR III (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III) trial demonstrated that intraventricular alteplase did not improve functional outcomes overall compared with saline. Therefore, routine use is not recommended, and therapy should be individualized.[26]

In selected patients with large IVH managed with an EVD for obstructive hydrocephalus, intraventricular alteplase may be considered in experienced centers to accelerate clot clearance. The CLEAR III (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III) trial demonstrated that intraventricular alteplase did not improve functional outcomes overall compared with saline. Therefore, routine use is not recommended, and therapy should be individualized.[26] In patients with spontaneous ICH receiving antiplatelet therapy, the PATCH (Platelet Transfusion in Cerebral Hemorrhage) trial found that platelet transfusion worsened outcomes, supporting the avoidance of routine transfusion unless a specific surgical indication exists.[27] The TICH-2 (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage) trial demonstrated that tranexamic acid modestly reduced hematoma expansion but did not improve functional outcomes, indicating that routine administration for all patients with ICH is not warranted.[28] Minimally invasive catheter evacuation with alteplase was evaluated in the MISTIE III (Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation Phase III) trial and demonstrated an acceptable safety profile. However, the procedure did not improve primary functional outcomes overall. Improved outcomes were observed in patients achieving a small residual hematoma volume, suggesting the benefit depends on surgical technique and patient selection.[29] Early minimally invasive parafascicular evacuation in the ENRICH (Early Minimally-Invasive Removal of Intracerebral Hemorrhage) trial improved functional outcomes in selected patients with supratentorial ICH, supporting this approach as a viable early surgical option in appropriately selected cases.[30] In factor Xa inhibitor–associated ICH, the ANNEXA-I (Andexanet Alfa, a Factor Xa Inhibitor Antidote) trial demonstrated that andexanet alfa improved hemostatic control and reduced hematoma expansion compared with usual care. The intervention was associated with increased thrombotic events, highlighting the need for individualized use.[31]

Prognostication in patients with ICH is critical. Underestimation may result in unnecessary interventions and prolonged hospitalization, whereas overestimation may lead to premature limitation of care. Key predictors of early neurologic deterioration and mortality include hematoma expansion, IVH, and hyperglycemia, with perihematomal edema contributing to secondary injury.

Hematoma E xpansion Hematoma expansion is an independent predictor of early neurologic deterioration and mortality. Most expansion occurs within the first few hours and may continue up to 24 hours after symptom onset. The CTA spot sign, representing contrast extravasation, indicates increased risk of hematoma expansion and exhibits heterogeneous morphology, varying in shape and size according to imaging timing relative to symptom onset. Management emphasizes rapid assessment, blood pressure control, correction of coagulopathy or antithrombotic effects when present, and surgical evacuation in selected patients. Hemostatic agents, such as recombinant factor VIIa, are not used routinely because clinical benefit remains uncertain, and thromboembolic risk is present. Perihematomal Edema Perihematomal edema arises from vasogenic and cytotoxic effects triggered by hematoma formation, producing mass effect on surrounding neural structures. Edema typically progresses over the first several days and may peak approximately 1 to 2 weeks after onset. Management aims to prevent and treat intracranial hypertension using supportive measures, including head-of-bed elevation and analgesia or sedation as clinically indicated. Hyperosmolar therapy with hypertonic saline or mannitol may be employed when necessary. Brief hyperventilation can serve as a temporizing measure in cases of impending herniation. Seizures Episodes confirmed by clinical examination or EEG should be treated with antiseizure medication. Routine prophylaxis is not recommended in patients without clinical suspicion of seizures. The selection of antiepileptic drugs should consider the potential for drug interaction with the current existing medication regimen and potential contraindications. Intraventricular Hemorrhage with Hydrocephalus

Episodes confirmed by clinical examination or EEG should be treated with antiseizure medication. Routine prophylaxis is not recommended in patients without clinical suspicion of seizures. The selection of antiepileptic drugs should consider the potential for drug interaction with the current existing medication regimen and potential contraindications. Intraventricular Hemorrhage with Hydrocephalus IVH is an independent predictor of poor outcome, primarily through obstructive hydrocephalus, ICP elevation, and secondary injury. EVD placement is indicated to manage obstructive hydrocephalus and increased ICP. In selected patients with large IVH treated with an EVD, intraventricular alteplase may be considered at experienced centers to accelerate clot clearance. However, overall functional benefit remains uncertain. Lumbar drainage is not used routinely and should be reserved for selected cases of communicating hydrocephalus under specialist guidance. Other complications include venous thromboembolism, presenting as a DVT or pulmonary embolism; stress-induced hyperglycemia; hyperthermia or fever related to brain injury or infection; and hypertension resulting from neuroendocrine activation.[32]

Setting age-appropriate blood pressure limits and promoting adherence to prescribed antihypertensive therapy are critical. Counseling on modifiable risk factors, including smoking, excessive alcohol consumption, and high-fat diets, should be provided as indicated. Early recognition of stroke symptoms is essential because nonspecific initial manifestations may delay presentation and limit treatment options. Delays in seeking care reduce opportunities to prevent early deterioration in ICH, as in cases of hematoma expansion and hydrocephalus. Patient education should emphasize stroke warning signs, including sudden neurologic deficits, severe headache, vomiting, reduced consciousness, or seizures, particularly in individuals with uncontrolled hypertension or multiple risk factors, to encourage prompt medical attention.[33]

An interprofessional team approach is essential for the care of patients with Charcot–Bouchard aneurysms and ICH. Optimization of modifiable risk factors, particularly hypertension, by the primary care team constitutes the first step in management, accompanied by patient education regarding stroke signs and symptoms to promote early presentation to the emergency department. Baseline severity assessment in the emergency department should be performed for patients with spontaneous ICH, followed by rapid neuroimaging using CT or MRI to differentiate ischemic from hemorrhagic stroke. Initial management requires admission to an intensive care or stroke unit with neuroscience expertise among the physicians and nursing staff. Correction of coagulopathy should be guided by etiology. Platelet transfusion is generally avoided in antiplatelet-associated spontaneous ICH unless emergent neurosurgery is planned. Vitamin K antagonists should be withheld, and the international normalized ratio should be rapidly corrected with intravenous vitamin K and 4-factor prothrombin complex concentrate. Dabigatran-associated ICH requires the specific reversal agent idarucizumab. For ICH associated with the use of factor Xa inhibitors, including apixaban or rivaroxaban, andexanet alfa is the preferred reversal agent where available. Thromboembolic risk and limited availability may necessitate the use of prothrombin complex concentrate according to local protocols and patient factors. Pneumatic compression of the lower extremities should be initiated from day 1 of hospitalization to prevent DVT. Patients presenting with an SBP of 150 to 220 mm Hg and without contraindications to acute lowering should be treated with a goal of 140 mm Hg, maintaining SBP within 130 to 150 mm Hg and avoiding SBP below 130 mm Hg. Blood glucose should be monitored to prevent hyperglycemia or hypoglycemia. Seizures should be managed, and dysphagia assessed to reduce the risk of aspiration pneumonia.

Patients presenting with an SBP of 150 to 220 mm Hg and without contraindications to acute lowering should be treated with a goal of 140 mm Hg, maintaining SBP within 130 to 150 mm Hg and avoiding SBP below 130 mm Hg. Blood glucose should be monitored to prevent hyperglycemia or hypoglycemia. Seizures should be managed, and dysphagia assessed to reduce the risk of aspiration pneumonia. All medications, including intravenous fluids, should undergo pharmacist review in the context of the complete medication record to identify interactions, verify dosing and administration, and provide recommendations to the clinical team as needed. Nursing staff must ensure correct medication administration and recognize potential adverse effects to alert clinicians promptly. Interprofessional collaboration among physicians, pharmacists, and nursing staff enhances patient safety and optimizes outcomes. Early neurological deterioration is common after ICH, particularly within the first 24 hours. Management should occur in a dedicated stroke unit or neurocritical care setting with neurosurgical capability and standardized protocols for blood pressure control, anticoagulant reversal, ICP and hydrocephalus management, and rapid repeat imaging in response to neurological changes. Patients requiring surgical intervention due to deterioration should be referred to neurosurgery promptly to optimize outcomes. Access to interprofessional rehabilitation during hospitalization, with continuation of services in the community and at home, is essential to promote functional recovery.